Monday, February 14, 2022

February 14, 2022 at 04:11PM ATryn

Product approval information is indicated for the prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/eprPEax

No comments:

Post a Comment